CureVac (NASDAQ:CVAC) Trading Up 4.7% – Time to Buy?

CureVac (NASDAQ:CVAC)’s share price rose 4.7% on Thursday . The company traded as high as $4.32 and last traded at $4.26. Approximately 356,735 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 1,710,864 shares. The stock had previously closed at $4.07.

CureVac Trading Down 1.9 %

The company has a 50 day moving average of $3.21 and a two-hundred day moving average of $3.17. The stock has a market capitalization of $917.91 million, a PE ratio of 7.45 and a beta of 2.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.

Hedge Funds Weigh In On CureVac

Several hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. purchased a new position in shares of CureVac in the second quarter worth $8,237,000. Jane Street Group LLC raised its stake in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock worth $235,000 after acquiring an additional 55,867 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in CureVac by 99.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock worth $147,000 after acquiring an additional 21,999 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of CureVac by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock valued at $127,000 after purchasing an additional 16,792 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of CureVac in the second quarter worth about $108,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.